Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PDE8B | O95263 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL901643 | 0.80 | ALDH1A1 (0.33) | SLC6A3MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL343088 | 0.80 | ALDH1A1 (0.33) | SLC6A3MEN1KMT2AALDH1A1HPGD | |
| Water SCHEMBL27791399 | 0.79 | EPHX2 (0.41) | EPHX2ALDH1A1HSD17B10LMNAPOLB | |
| SCHEMBL7335663 | 0.74 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL7347720 | 0.74 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL1977433 | 0.74 | EPHX2 (0.59) | EPHX2MEN1KMT2APOLB | |
| SCHEMBL6687035 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL6871695 | 0.72 | EPHX2 (0.58) | EPHX2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL2411177 | 0.72 | EPHX2 (0.62) | EPHX2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL18845118 | 0.72 | EPHX2 (0.62) | EPHX2MEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | EPHX2 3190/4885SLC6A3 4646/4885MEN1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.